Protein Characterization
Comprehensive protein characterization is a fundamental component of antibody and antibody-oligonucleotide conjugate (AOC) development, providing essential information on molecular identity, structural integrity, purity, stability, and functional properties. Protheragen provides integrated protein characterization services to support antibody and AOC programs from early candidate evaluation through CMC development. By combining advanced analytical technologies and scientific expertise, we help define critical quality attributes (CQAs), ensure product consistency, and generate reliable analytical data to support process development and regulatory submissions.
Overview of Protein Characterization
Protein characterization plays a critical role in understanding the quality attributes of therapeutic antibodies and complex biologics. Detailed characterization of molecular structure, physicochemical properties, and biological activity provides important insights for evaluating product quality, optimizing manufacturing processes, and ensuring regulatory compliance.
For antibody therapeutics, characterization focuses on key attributes including molecular identity, purity, aggregation profile, higher-order structure, glycosylation patterns, and biological function. For antibody-oligonucleotide conjugates (AOCs), additional characterization is required to evaluate conjugation-related attributes, such as conjugation efficiency, drug-to-antibody ratio (DAR), payload distribution, and molecular stability.
A comprehensive characterization strategy enables accurate assessment of product quality throughout development and supports the establishment of robust analytical methods for IND, clinical, and commercial manufacturing stages.
Fig.1 Overview of the methods of molecular structural analysis and functional assessment. (Wang X, et al., 2018)
Our Services
Protheragen provides comprehensive characterization solutions covering structural, physicochemical, and functional evaluation of antibody and AOC molecules.
Primary Structure Characterization
Primary structure analysis provides confirmation of molecular identity and sequence integrity.
Our services include:
- Intact mass determination
- Peptide mapping analysis
- Amino acid sequence confirmation
- Disulfide bond analysis
- Post-translational modification (PTM) identification
These analyses support molecular identity confirmation and help establish product characterization profiles.
Higher-Order Structure Analysis
Evaluation of higher-order structures is essential for understanding protein folding, stability, and functional performance.
Characterization services include:
- Secondary structure analysis
- Tertiary structure evaluation
- Conformational stability assessment
- Thermal stability analysis
- Structural comparability evaluation
Advanced biophysical techniques are applied to assess structural integrity and identify potential molecular changes.
Purity and Impurity Characterization
Purity evaluation is critical for determining product quality and supporting process optimization.
Our analytical capabilities include:
- Size variant analysis
- Aggregation assessment
- Fragment analysis
- Host cell protein (HCP) detection
- Residual DNA analysis
- Process-related impurity evaluation
These analyses support purification process development and quality control strategy establishment.
Glycosylation and Post-Translational Modification Analysis
Glycosylation and other post-translational modifications can significantly influence antibody stability, activity, and pharmacological properties.
Protheragen provides:
- N-glycan profiling
- Glycosylation pattern analysis
- Oxidation and deamidation analysis
- Charge variant analysis
- Modification site identification
These studies help evaluate product consistency and define important quality attributes.
Functional Characterization
Functional characterization evaluates whether antibody molecules maintain expected biological activity.
Services include:
- Antigen-binding activity evaluation
- Binding affinity analysis
- Cell-based bioactivity assays
- Fc receptor interaction analysis
- Mechanism-related functional evaluation
Functional characterization supports product quality assessment and potency assay development.
AOC-Specific Characterization
Due to the complexity of antibody-oligonucleotide conjugates, specialized analytical strategies are required to evaluate conjugation-related properties.
Protheragen supports AOC characterization through:
- Conjugation efficiency analysis
- Drug-to-antibody ratio (DAR) evaluation
- Payload distribution analysis
- Linker stability assessment
- Antibody and oligonucleotide integrity analysis
- Conjugate stability evaluation
These analyses provide critical information for AOC quality evaluation and CMC development.
Key Capabilities
Protheragen combines advanced analytical platforms and multidisciplinary expertise to deliver comprehensive characterization solutions for antibody and AOC therapeutics. Our capabilities cover molecular identity confirmation, structural analysis, purity assessment, stability evaluation, and functional characterization to support the definition of critical quality attributes (CQAs). By integrating orthogonal analytical approaches, we provide reliable characterization data that supports candidate selection, process development, analytical method establishment, and regulatory submission preparation.
| Characterization Area |
Evaluation Focus |
| Molecular Characterization |
Identity confirmation, sequence analysis, molecular integrity |
| Structural Characterization |
Higher-order structure, conformational stability |
| Purity & Impurity Analysis |
Aggregation, fragments, process-related impurities |
| Glycosylation Analysis |
N-glycan profiling, PTM evaluation |
| Functional Characterization |
Binding activity, potency, biological function |
Supporting Analytical Technologies
Protheragen utilizes advanced analytical platforms to support comprehensive characterization of antibody and AOC molecules, including:
- LC-MS / High-resolution Mass Spectrometry
- Size Exclusion Chromatography (SEC-HPLC)
- Ion Exchange Chromatography (IEX-HPLC)
- Capillary Electrophoresis (CE-SDS)
- Dynamic Light Scattering (DLS)
- Differential Scanning Calorimetry (DSC)
- Multi-Attribute Method (MAM)
- Glycan Analysis Platforms
These technologies enable multi-dimensional characterization of molecular quality attributes and support robust CMC development.
Why Choose Protheragen
- Comprehensive Characterization Strategy
Protheragen applies integrated analytical strategies to evaluate antibody and AOC molecules from multiple perspectives, ensuring a complete understanding of molecular properties and product quality attributes.
- Advanced Analytical Platforms
Our characterization workflows utilize orthogonal analytical technologies to provide accurate and reliable data for structural, physicochemical, and functional evaluation.
- Expertise in Complex Biologics
With experience in antibody and conjugated therapeutic development, Protheragen understands the analytical challenges associated with complex biologics, including AOC molecular characterization.
- CMC-Oriented Analytical Support
Characterization results are closely integrated with process development, quality evaluation, and regulatory requirements, supporting efficient progression from early development to clinical manufacturing.
Reliable protein characterization is essential for understanding therapeutic molecule quality and establishing a robust CMC development strategy. Protheragen provides integrated analytical solutions for antibody and AOC programs, delivering critical insights into molecular structure, quality attributes, and functional performance. Through advanced characterization technologies and CMC-focused expertise, Protheragen supports clients in accelerating antibody and AOC candidates toward successful clinical development and commercialization. Contact us to explore comprehensive protein characterization solutions for your antibody and AOC programs. Our experts are ready to support your project with advanced analytical capabilities and CMC-focused development strategies.
Reference
- Wang X, et al. "Molecular and functional analysis of monoclonal antibodies in support of biologics development" Protein Cell. 2018; 9(1):74-85.
